EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network

Christoph Blazejak, Mathias Oymanns, René Stranzenbach, Uwe Hillen, Christina Mitteldorf, Jan P Nicolay, Marion Wobser iD, Philipp Schrüfer, Janika Gosmann, Ulrike Wehkamp, Nina Booken iD, Alexander Kreuter iD und 5 weitere

Cancers · 28.12.2025 · 18 (1) · 97

DOI: 10.3390/cancers18010097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 28.12.2025. Verfasst von Christoph Blazejak und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) are aggressive forms of cutaneous T-cell lymphoma (CTCL) for which treatment options are limited and prognosis is poor. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated high response rates in patients with CD30 expression ≥ 10%. However, data on its efficacy in cases with low CD30 expression (

Schlagwörter

Stichwörter der Autor:innen

CD30CTCLSézary syndromebrentuximab vedotincutaneous T-cell lymphomamycosis fungoidestreatment

Autor:innen und Institutionen

  • Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany.
  • Department of Dermatology, Universitätsklinikum Bochum, 44801 Bochum, Germany.
  • Dermatology Practice Dr. R. Stranzenbach, 58285 Gevelsberg, Germany.
  • Department of Dermatology, Vivantes Klinikum Neukölln, 12351 Berlin, Germany.
  • MVZ Dermatopathologie Duisburg Essen GmbH, 45147 Essen, Germany.
  • Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, 37075 Göttingen, Germany.

ORCID-Profile: Marion Wobser, Nina Booken, Alexander Kreuter, Rudolf Stadler, Chalid Assaf

Zitieren

APA

Blazejak, C., Oymanns, M., Stranzenbach, R., Hillen, U., Mitteldorf, C., Nicolay, J. P., Wobser, M., Schrüfer, P., Gosmann, J., Wehkamp, U., Booken, N., Kreuter, A., Dippel, E., Klemke, C. D., Weyermann, M., Stadler, R., & Assaf, C. (2025). Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. Cancers, 18(1), 97. https://doi.org/10.3390/cancers18010097

Vancouver

Blazejak C, Oymanns M, Stranzenbach R, Hillen U, Mitteldorf C, Nicolay JP, et al. Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. Cancers. 2025;18(1):97. doi:10.3390/cancers18010097

BibTeX
@article{Blazejak2025,
  author = {Blazejak, Christoph and Oymanns, Mathias and Stranzenbach, René and Hillen, Uwe and Mitteldorf, Christina and Nicolay, Jan P and Wobser, Marion and Schrüfer, Philipp and Gosmann, Janika and Wehkamp, Ulrike and Booken, Nina and Kreuter, Alexander and Dippel, Edgar and Klemke, Claus-Detlev and Weyermann, Maria and Stadler, Rudolf and Assaf, Chalid},
  title = {Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network},
  journal = {Cancers},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {97},
  doi = {10.3390/cancers18010097}
}
Kostenlos starten →